Is XXXX survival improving?

@entity1 @entity172 @entity0 @entity4349 @entity5
BACKGROUND: Despite advances in therapies for @entity0 , improvement in survival for @entity1 with recurrent or metastatic @entity0 has been difficult to establish. The objective of the current study was to determine whether the survival of @entity1 with recurrent @entity0 has improved from 1974 to 2000. METHODS: The authors analyzed the survival experience of 834 @entity1 who developed recurrent @entity0 between November 1974 and December 2000. All @entity1 had been treated previously with adjuvant @entity4349 -based protocols. @entity1 were divided into five consecutive groups based on year of @entity0 recurrence, and survival was compared across the five groups. Because some prognostic variables were divided unevenly divided among the cohorts, a multivariate model was created to determine the association of year of recurrence and survival after accounting for other prognostic factors. RESULTS: In the unadjusted analysis, there was a statistically significant improvement in survival across the five groups, and the more recent cohorts had longer survival (P < 0.001). Other variables that predicted longer survival after @entity0 recurrence included smaller @entity5 size, lower stage of disease, fewer lymph nodes involved, longer disease-free interval, @entity172 receptor-positive @entity5 , and nonvisceral dominant site of disease recurrence. In the multivariate analysis, which adjusted for these prognostic factors, year of recurrence was associated with a trend toward improved survival, with a 1% reduction in risk for each increasing year. CONCLUSIONS: For these cohorts of @entity1 , the authors present data suggesting that the prognosis for @entity1 with recurrent @entity0 improved between 1974 and 2000.
